HomeAI · summaries
Storia in 5 fonti
Roche stakes $700M on Nurix’s protein-degrading drug
Potentially worth up to $2.3 billion, the collaboration is a bet that drugs able to eliminate the “BTK” enzyme will prove superior to existing medicines that block its activity.
Confronto fonti
5 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
Roche stakes $700M on Nurix’s protein-degrading drug
Potentially worth up to $2.3 billion, the collaboration is a bet that drugs able to eliminate the “BTK” enzyme will prove superior to existing medicines that block its activity.
- ·
swissinfo.ch
Roche joins Californian Nurix oncology programme
Roche pledges $700 million to join research on the drug bexobrutideg.
- ·
Roche to Pay Nurix as Much as $2.3 Billion in Cancer Deal
(Bloomberg) -- Roche Holding AG agreed to pay Nurix Therapeutics Inc. as much as $2.3 billion for rights to an experimental blood-cancer drug, betting it can help patients whose…
- ·
endpoints.news
Nurix to work with Roche on BTK degrader in pact worth up to $2.3B
Roche is set to pay Nurix Therapeutics $700 million upfront to collaborate on a BTK degrader for B-cell malignancies.
- ·
benzinga.com
Nurix Therapeutics Gains Ground As Roche Partnership Targets Growing B-Cell Blood Cancer Market - Nurix T
Nurix Therapeutics and Roche sign a BTK degrader partnership worth up to $2.3 billion, supporting Phase 3 plans for bexobrutideg.
- ·
investors.com
Roche Inks $2.3 Billion Deal, Sending Biotech Stock Flying
Shares bounded off their 50-day line Monday after inking a deal with Roche for a BTK-degrading drug.